"Given the fact that prior to 2007 we only knew of three genetic risk factors for Crohn's disease truly represents tremendous progress in our ability to understand Crohn's disease. Specifically this study is indicating which biological pathways specifically lead to Crohn's disease as well as which of these pathways are in common with other immune mediated diseases such as autoimmune diabetes, lupus and rheumatoid arthritis," says Dr. Rioux, co-author of the current study.
"This is breakthrough research for patients with Crohn's disease and one of the most significant advances in our understanding of this disease, to date," says Dr. Silverberg, co-author of the study.
"Our research was successful because of the international collaborative approach."
Finally, Rioux stated that "the hope is that the identification of the biological paths that lead to Crohn's disease can be translated into useful clinical tools for improved diagnosis, classification and treatment of this chronic disease."
In total, the effort constituted a collaboration between clinical genetic researchers from 25 institutions across North America including Yale University, University of Pittsburgh, Universit de Montral, University of Toronto, Johns Hopkins University, and Cedars-Sinai Medical Center in Los Angeles the United Kingdom, Belgium and France. The team is committed to further advancing these results in collaboration with investigators from additional countries. Support for the study came from several organizations, including the National Institute of Diabetes and Digestive and Kidney Diseases, through the Inflammatory Bowel Disease Genetic Consortium.
|Contact: Doris Prince|
University of Montreal